---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295678916.md"
description: "Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress."
datetime: "2026-08-12T14:11:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295678916.md)
  - [en](https://longbridge.com/en/news/295678916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295678916.md)
generator: "portal-rs"
---

# 

Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.

### Related Stocks

- [AVLN.US](https://longbridge.com/en/quote/AVLN.US.md)

## Related News & Research

- [Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levels](https://longbridge.com/en/news/299663715.md)
- [Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statement](https://longbridge.com/en/news/299360082.md)
- [Tesla's Q3 Delivery Beat Is Just the Start: Gene Munster Says TSLA Will ‘Crush Traditional Automakers’](https://longbridge.com/en/news/300968018.md)
- [Is Oracle Stock a Good Buy While It's Trading Below $150?](https://longbridge.com/en/news/300960808.md)
- [‘One for the Kids,’ Says Top Investor About SpaceX Stock](https://longbridge.com/en/news/300955937.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**